Letters to the Editor

Garfinkel PE Bagby RM Waring EM Dorion B. Boundary violations and personality traits among psychiatrists. Can J Psychiatry 1997;42:758–63.

Sendbuehler JM Kincel RL Nemeth G Oertel J. Dimension of seriousness in attempted suicide: Significance of Mf scale in suicidal MMPI profiles. Psychol Rep 1979;44:343–61.

Butcher JN Williams CL . Essentials of MMPI-2 and MMPI-A interpretation. Minneapolis (MN): University of Minnesota Press; 1992.

Benazzi F. Severe anticholinergic side effects with venlafaxine-fluoxetine combination. Can J Psychiatry 1997;42:980–1.

Holliday SM Benfield P. Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280–94.

Abdelmawla AH Bitsios P Langley RW Szabadi E Bradshaw CM . Comparison of venlafaxine, desipramine and paroxetine on autonomic functions in man. J Psychopharmacol 1997;11(A Suppl):28S.

Szabadi E Bradshaw CM . Autonomic pharmacology of α2-adrenoceptors. J Psychopharmacol 1996; 10(Suppl):6S–18S.

Izumi H Nakamura I Karita K. Effects of clonidine and yohimbine on parasympathetic reflex salivation and vasodilatation in cat SMG. Am J Physiology 1995;268:R1196–R1202.

De Ponti F Giaroni C Cosentino M Lecchini S Frigo G. Adrenergic mechanisms in the control of gastrointestinal motility: From basic science to clinical applications. Pharmacol Ther 1996;69:59–78.

Gilmartin B Bullimore NIA Rosenfield M Winn B Owens H. Pharmacological effects on accommodative adaptation. Optom Vis Sci 1992;69:276–82.

Bitsios P Langley RW Szabadi E Bradshaw CM . Comparison of venlafaxine, desipramine and paroxetine on the pupillary light reflex in man. J Psychopharmacol 1997;ll(A Suppl):28S.

Lazowick AL Levin GM . Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995;29:1284–5.

Coupland NJ Bell CJ Potokar JP . Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356–62.

Zajecka J Tracy KA Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997;58:291–7.

Schatzberg AF Haddad P Kaplan EM Lejoyeux M Rosenbaum JF Young AH , and others. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry 1997;58(7 Suppl):5S–10S.

Lejoyeux M Ades J. Antidepressant discontinuation: A review of the literature. J Clin Psychiatry 1997;58(7 Suppl):11S–6S.

Young AH Currie A. Physician's knowledge of antidepressant withdrawal effects: A survey. J Clin Psychiatry 1997;58(7 Suppl):28S–30S.

Schatzberg AF Haddad P Kaplan EM Lejoyeux M Rosenbaum JF Young AH , and others. Possible biologic mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry 1997;58(7 Suppl):23S–7S.

Tulloch IF Johnson AM . The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 1992;53(2 Suppl):7S–12S.

Guthrie SK . Sertraline: A new specific serotonin reuptake blocker. Ann Pharmacother 1991;25:952–61.

Black DW Wesner R Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146–9.

Anderson K Alistair C Gaudet M Gautam M Kerr PJ Pecher M , and others. A cross-sectional study of private psychiatric practices under a single-payer health care system. Can J Psychiatry 1997;42:395–401.

Coupland NJ Bell CJ Potokar JP . Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356–62.

Schatzberg AF Haddad P Kaplan EM Lejoyeux M Rosenbaum JF Young AH Zajecka J. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry 1997;58(7 Suppl):5S–10S.

Delbressine LPC Vos RME . The clinical relevance of preclinical data: Mirtazapine, a model compound. J Clin Psychopharmacol 1997;17:29S–33S.

Benazzi F. Venlafaxine withdrawal symptoms [letter]. Can J Psychiatry 1996;41:487.

de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(4 Suppl):19S–25S.

Preskorn SH . Selection of an antidepressant: Mirtazapine. J Clin Psychiatry 1997;58(6 Suppl):3S–8S.

Goodwin GM . How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996;57(4 Suppl):9S–13S.

Babe KS Serafin WE . Histamine, bradykinin, and their antagonists. In: Hardman JG Limbird LE Molinoff PB Ruddon RW Goodman Gilman A , editors. Goodman & Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996. p 592.

Frazer A. Antidepressants. J Clin Psychiatry 1997;58(6 Suppl):19S–25S.

Nemeroff CB DeVane CL Pollock BG . Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311–20.

Benazzi F. DSM-III-R schizophreniform disorder with good prognostic features: A 6-year follow-up. Can J Psychiatry 1998;43:180–2.

Strakowski SM . Diagnostic validity of schizophreniform disorder. Am J Psychiatry 1994;151:815–24.

Andreasen NC Flaum M Arndt S. The comprehensive assessment of symptoms and history (CASH). Arch Gen Psychiatry 1992;49:615–23.

Tsuang MT Winokur G Crowe RR . Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. Br J Psychiatry 1980;137:497–504.

Maj M Starace F Pirozzi R. A family study of DSM-III-R schizoaffective disorder, depressive type, compared with schizophrenia and psychotic and nonpsychotic major depression. Am J Psychiatry 1991;148:612–6.

Andreasen NC Endicott J Spitzer RL Winokur G. The family history method using diagnostic criteria. Arch Gen Psychiatry 1977;34:1229–35.

Roy MA Walsh D Kendler KS . Accuracies and inaccuracies of the family history method: A multivariate approach. Acta Psychiatr Scand 1996;93:224–34.

Thompson WD Orvaschel H Prusoff BA Kidd KK . An evaluation of the family history method for ascertaining psychiatric disorders. Arch Gen Psychiatry 1982;39:53–8.